Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft

Status Completed

Clinical Trial Summary

The goal of this study is to establish if mesenchymal stem cell augmentation improves graft incorporation and to analyze the cytokine environment of the joint after osteochondral allograft transplantation (OCA) with and without intra-articular bone marrow aspirate concentrate (BMAC) injection. Information learned from this study can be used to biochemically compare treatment response and to assess emerging therapeutic options that may positively alter the biochemical environment in patients who suffer from articular cartilage disorders.

Clinical Trial Description

Articular cartilage injuries in the knee continue to grow in number as detection and treatment options have advanced. Treatment options, including microfracture, autologous chondrocyte (cells that make cartilage) implantation, osteochondral grafting and meniscus transplantation can hopefully deter the progression of degeneration and have promise to function as disease modifying solutions. Osteochondral allograft transplantation (OCA) has emerged as a preferred method of treating large focal chondral defects as it structurally replaces the cartilage and often involved sub-chondral bone with native hyaline cartilage and bone. The results of OCA are successful with greater than 85% survival at 5-year follow-up. Failure can occur due to a lack of boney integration or low chondrocyte viability. Therefore, anything to enhance the graft augmentation process may be useful in preventing failure. The purpose of this prospective, randomized study is to determine the effect of bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells on improving graft incorporation and preventing failure. The effect of BMAC on the graft and intra-articular knee environment will be evaluated using 3 techniques: computed tomography (CT) imaging, synovial fluid cytokine analysis, and serum biomarker analysis. Information learned from this study can be used to biochemically compare treatment response and to assess emerging therapeutic options that may positively alter the biochemical environment in patients undergoing osteochondral allograft transplantation. ;

Study Design

Related Conditions & MeSH terms

Cartilage Injury

Clinical Trial Details

NCT number	NCT04739930
Study type	Interventional
Source	Rush University Medical Center
Contact
Status	Completed
Phase	N/A
Start date	March 2, 2018
Completion date	January 12, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03479775` - Muscle Function and Traumatic Knee Injury in Sports
Recruiting	`NCT03321812` - Clinical Study of Decalcification Bone Scaffold for Cartilage Lesions of the Knee	N/A
Recruiting	`NCT06082531` - Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis	N/A
Completed	`NCT06078072` - Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
Completed	`NCT04889443` - Spontaneous Healing of ARticular Cartilage (SHARC)
Completed	`NCT04118023` - 7T MRI to Evaluate Cartilage Defects in the Knee
Active, not recruiting	`NCT01458782` - ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee	N/A
Recruiting	`NCT03477942` - Impact of Mesenchymal Stem Cells in Knee Osteoarthritis	Phase 1
Completed	`NCT01473199` - BioPoly RS Knee Registry Study for Cartilage Defect Replacement	N/A
Recruiting	`NCT05124613` - The Impact of Covid-19 on Patients Waiting for Knee Surgery
Recruiting	`NCT06344481` - The Hyalex First-in-Human Study	Phase 1
Active, not recruiting	`NCT03873545` - Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella
Recruiting	`NCT05328674` - Clinical and Comparative Evaluation of the Treatment Results of Arthroscopic Reconstruction of Cartilage Defects in the Knee Joint With the Use of Autogenous Cartilage Graft With PRP GF (Platelet-rich Plasma With Growth Factors)	N/A
Recruiting	`NCT04184687` - The Treatment of Cartilaginous Lesions and Concomitant Anterior Cruciate Ligament Reconstruction	N/A
Terminated	`NCT04301258` - ProChondrix® CR Articular Cartilage Restoration Evaluation (PACE) Registry
Completed	`NCT02696876` - Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair	N/A
Completed	`NCT02637505` - Norwegian Cartilage Project - Microfracture	N/A
Recruiting	`NCT04135950` - Prospective Registry of Anterior Cruciate Ligament Reconstructions
Completed	`NCT03024801` - Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury	N/A
Completed	`NCT01041001` - Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms